Tesamorelin

• GH secretion stimulation by binding to GHRH receptors in the anterior pituitary, increasing GH release and elevating insulin like growth factor 1 (IGF 1) levels downstream.
• Reduction in visceral fat through stimulation of lipolysis, contributing to reductions in abdominal fat in research models involving lipodystrophy and obesity.
• Metabolic enhancement through improvements in lipid profiles, glucose metabolism, and insulin sensitivity, which is why it is discussed in metabolic syndrome and obesity related research contexts.

Research involving Tesamorelin commonly explores

• Visceral fat reduction with emphasis on deep abdominal fat, including in research settings involving HIV associated lipodystrophy, metabolic syndrome, and central obesity.
• Improved body composition by supporting lean muscle mass retention while reducing fat mass, contributing to muscle definition and overall metabolic health.
• Metabolic benefits including support for improved cholesterol and triglyceride profiles and improved insulin sensitivity, with potential downstream relevance to Type 2 diabetes risk models.

Tesamorelin is generally described as well tolerated in research settings, but some side effects may experience

• Mild injection site irritation such as redness or swelling.
• Transient water retention can occur and may subside as the body adapts to GH stimulation.
• Nausea or mild gastrointestinal discomfort is reported in some cases.